BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 15930292)

  • 1. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels.
    He Y; Rajantie I; Pajusola K; Jeltsch M; Holopainen T; Yla-Herttuala S; Harding T; Jooss K; Takahashi T; Alitalo K
    Cancer Res; 2005 Jun; 65(11):4739-46. PubMed ID: 15930292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
    He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
    J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular control of lymphatic metastasis.
    Achen MG; Stacker SA
    Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model.
    Quagliata L; Klusmeier S; Cremers N; Pytowski B; Harvey A; Pettis RJ; Thiele W; Sleeman JP
    Clin Exp Metastasis; 2014 Mar; 31(3):351-65. PubMed ID: 24379135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis.
    Burton JB; Priceman SJ; Sung JL; Brakenhielm E; An DS; Pytowski B; Alitalo K; Wu L
    Cancer Res; 2008 Oct; 68(19):7828-37. PubMed ID: 18829538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
    Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
    Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis.
    Matsumoto M; Roufail S; Inder R; Caesar C; Karnezis T; Shayan R; Farnsworth RH; Sato T; Achen MG; Mann GB; Stacker SA
    Clin Exp Metastasis; 2013 Aug; 30(6):819-32. PubMed ID: 23591595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
    Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
    J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion.
    Tacconi C; Correale C; Gandelli A; Spinelli A; Dejana E; D'Alessio S; Danese S
    Gastroenterology; 2015 Jun; 148(7):1438-51.e8. PubMed ID: 25754161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.
    Yang H; Kim C; Kim MJ; Schwendener RA; Alitalo K; Heston W; Kim I; Kim WJ; Koh GY
    Mol Cancer; 2011 Apr; 10():36. PubMed ID: 21481239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
    Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
    Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.
    Wen J; Fu AF; Chen LJ; Xie XJ; Yang GL; Chen XC; Wang YS; Li J; Chen P; Tang MH; Shao XM; Lu Y; Zhao X; Wei YQ
    Int J Cancer; 2009 Jun; 124(11):2709-18. PubMed ID: 19219913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
    García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
    J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
    Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
    Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of FLT4 suppresses metastasis of melanoma cells by impaired lymphatic vessels.
    Lee JY; Hong SH; Shin M; Heo HR; Jang IH
    Biochem Biophys Res Commun; 2016 Sep; 478(2):733-8. PubMed ID: 27507214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer.
    Shimizu K; Kubo H; Yamaguchi K; Kawashima K; Ueda Y; Matsuo K; Awane M; Shimahara Y; Takabayashi A; Yamaoka Y; Satoh S
    Cancer Sci; 2004 Apr; 95(4):328-33. PubMed ID: 15072591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.
    Roberts N; Kloos B; Cassella M; Podgrabinska S; Persaud K; Wu Y; Pytowski B; Skobe M
    Cancer Res; 2006 Mar; 66(5):2650-7. PubMed ID: 16510584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor.
    Lin J; Lalani AS; Harding TC; Gonzalez M; Wu WW; Luan B; Tu GH; Koprivnikar K; VanRoey MJ; He Y; Alitalo K; Jooss K
    Cancer Res; 2005 Aug; 65(15):6901-9. PubMed ID: 16061674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of VEGF ligands and receptors in prostate cancer.
    Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED
    Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model.
    Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S
    Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.